The anti-CTLA-4 ipilimumab, approved to treat metastatic melanoma, is under consideration for use in combined treatments for breast cancer, to prevent T cell anergy (Voutsadakis, 2016). This evidence concerns the gene CTLA4 and breast carcinoma.